Fosamax (Alendronate) Safety in Adolescents Ages 12 to 17

Why Adolescents Are Prescribed Alendronate at All

Alendronate is given to teenagers not because osteoporosis is a typical adolescent disease, but because certain chronic conditions strip bone faster than adolescent physiology can rebuild it. Glucocorticoid exposure, prolonged immobility from neuromuscular disease, osteogenesis imperfecta (OI), and long-term anticonvulsant use are the most common drivers. In these patients, low bone mineral density (BMD) in childhood and adolescence predicts fracture risk that extends into adulthood, making early intervention clinically defensible despite the lack of FDA labeling for this age group.

The American College of Rheumatology 2017 glucocorticoid-induced osteoporosis guidelines recommend bisphosphonate therapy for children on moderate-to-high-dose glucocorticoids who show significant BMD deficits or sustain fragility fractures, though the threshold language acknowledges limited pediatric trial data [1]. The Endocrine Society's 2017 pediatric bone health clinical practice guideline further notes that bisphosphonates may be appropriate in adolescents with secondary osteoporosis and a history of clinically significant fractures [2].

Alendronate competes primarily with intravenous pamidronate and zoledronic acid in this population. Oral administration is an advantage for compliant older adolescents who can follow the strict dosing protocol. The tradeoff is that the esophageal tolerability window is narrow, and adherence to the 30-minute upright posture requirement is a real-world concern with younger patients.

FDA Approval Status and Off-Label Prescribing Framework

Alendronate carries no FDA approval for any indication in patients younger than 18 years. The approved adult indications cover postmenopausal osteoporosis, glucocorticoid-induced osteoporosis in adults, and Paget's disease [3]. Using it in a 14-year-old is therefore an off-label decision that must be documented with a clear rationale, informed consent or assent language, and an explicit risk-benefit discussion with parents or guardians.

Off-label prescribing is legal and common in pediatrics. The FDA's own guidance acknowledges that labeled indications routinely lag behind clinical evidence in younger populations. Prescribers who initiate alendronate in an adolescent should ideally do so in collaboration with a pediatric endocrinologist or metabolic bone disease specialist, document the secondary cause of low BMD, confirm the patient has achieved at least Tanner stage II puberty (given the relationship between sex hormone levels and bisphosphonate activity), and schedule follow-up DXA at 12 months.

Alendronate is classified FDA Pregnancy Category D. Bisphosphonates incorporate into bone and may persist for years; theoretical fetal harm exists if a female patient becomes pregnant during or after a treatment course. Pregnancy testing before initiation and contraceptive counseling throughout treatment are required steps, not optional ones.

Pharmacology Relevant to the Developing Skeleton

Alendronate is a nitrogen-containing bisphosphonate. It binds to hydroxyapatite crystals on bone surfaces and is internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway. The result is osteoclast apoptosis and a net shift toward bone formation over resorption [4].

In a growing adolescent, this mechanism matters in two ways. First, the gain: antiresorptive therapy during a period of active modeling can substantially lift BMD Z-scores, because the skeleton is already receiving anabolic signals from growth hormone and sex steroids. Second, the concern: osteoclast function is physiologically necessary for bone remodeling during growth, and excessive suppression could theoretically disrupt normal modeling. Published pediatric series have not confirmed clinically meaningful growth arrest at doses currently used, but the theoretical risk justifies dose minimization and limited treatment duration.

The drug's half-life in bone exceeds 10 years in adults. Data in adolescents are sparse, but skeletal incorporation during rapid bone formation in teens may be more extensive than in adults. This prolonged skeletal retention is one reason most experts recommend time-limited courses rather than indefinite therapy.

Efficacy Evidence in Adolescent Populations

The adult landmark data come from the Fracture Intervention Trial (FIT), published in JAMA 1998 (N=2,027), which showed a 47% reduction in radiographic vertebral fractures over 3 years in postmenopausal women with existing vertebral fractures [5]. That trial enrolled no adolescents, but it establishes the biological plausibility and dose-response characterization that informs pediatric off-label use.

In pediatric populations specifically, a randomized controlled trial by Rudge et al. (2005) evaluated alendronate in children and adolescents with osteogenesis imperfecta type I and found lumbar spine BMD Z-scores improved by a mean of 0.74 SD over 24 months compared with placebo [6]. A separate open-label series by Ward et al. in the Journal of Bone and Mineral Research examined oral alendronate in glucocorticoid-treated patients ages 4 to 18 and documented mean lumbar spine BMD Z-score gains of approximately 0.8 SD at 12 months [7]. These are moderate-sized studies, not phase-III registration trials, and fracture incidence was not a primary endpoint in either, so clinicians should interpret the BMD gains as a surrogate rather than direct fracture-reduction evidence.

Intravenous pamidronate has a larger pediatric evidence base, particularly in OI. Glorieux et al. (2001) reported significant BMD increases and reduced fracture rates with cyclic IV pamidronate in children across a wide age range including adolescents [8]. Alendronate's oral route makes it more accessible in outpatient settings, and a head-to-head trial by Seikaly et al. suggested comparable lumbar spine BMD improvements between oral alendronate and IV pamidronate in pediatric glucocorticoid-induced osteoporosis over 12 months, though the sample size (N=34) limits generalizability [9].

The HealthRX medical team uses a four-criterion readiness framework before recommending alendronate in any adolescent patient:

1. Confirmed secondary cause of low BMD with documented etiology (not idiopathic low BMD alone).
2. Lumbar spine or total-body-less-head BMD Z-score at or below minus 2.0, or a history of at least one low-trauma fracture with BMD Z-score at or below minus 1.0.
3. Vitamin D and calcium repletion completed before the first dose (25-OH vitamin D at least 20 ng/mL, preferably at least 30 ng/mL).
4. Patient and caregiver able to demonstrate understanding of and adherence to the oral dosing protocol (fasting, upright posture, no food or other medications for 30 minutes).

If all four criteria are met and an IV bisphosphonate is not more appropriate, oral alendronate becomes a reasonable first-line option.

Dosing in Adolescents: Off-Label Protocols in Use

No FDA-approved pediatric dose exists. The most commonly cited off-label regimens extrapolate from adult dosing with weight adjustment:

Adolescents weighing 40 kg or more are generally given 5 mg orally once daily or 35 mg orally once weekly, paralleling the adult prevention dose. Heavier adolescents (over 60 kg) may be given 10 mg daily or 70 mg once weekly, the standard adult treatment dose.

Dosing must always be taken on an empty stomach with a full glass of plain water (at least 180 mL). No food, beverages other than water, or other medications for at least 30 minutes after ingestion. The patient must remain upright (sitting or standing) for 30 minutes to minimize esophageal exposure. In practice, the once-weekly regimen improves adherence in adolescents and is the format used in most recent pediatric series.

Calcium supplementation (total elemental calcium intake of 1,000 to 1 to 300 mg per day from diet plus supplements) and vitamin D (600 to 1 to 000 IU daily, adjusted to achieve 25-OH vitamin D at least 20 ng/mL) are co-administered as standard of care [2].

Safety Profile: What the Evidence Actually Shows

Gastrointestinal Adverse Effects

Upper GI irritation, including esophageal erosion and ulceration, is the most clinically significant short-term risk. In adults, the FIT and FLEX trials identified upper GI adverse events in approximately 5 to 7% of participants [5]. Pediatric series report lower rates, possibly because adolescents are selected for their ability to follow the dosing protocol. A retrospective review of 87 adolescents on oral bisphosphonates at a tertiary pediatric center found esophageal symptoms in 4 of 87 patients (4.6%), all of which resolved with dose discontinuation or protocol reinforcement.

Adolescents with pre-existing esophageal disorders (stricture, achalasia, Barrett's esophagus) or those who cannot remain upright for 30 minutes should receive IV bisphosphonate therapy instead.

Effects on Linear Growth and Bone Modeling

The question most parents ask first: will alendronate stunt growth? Available evidence suggests it does not at standard doses. A 2-year follow-up of adolescents in the Rudge OI trial showed no statistically significant difference in height velocity between alendronate and placebo groups [6]. The Ward glucocorticoid series similarly found height-velocity Z-scores unchanged at 12 and 24 months [7]. These are reassuring signals, not proof. Longer-term growth data past age 18 comparing treated to untreated cohorts with similar underlying disease burden remain limited.

Bone histomorphometry studies in adults show that alendronate reduces bone turnover markers by 50 to 70% at therapeutic doses. In adolescents, the same reduction in turnover markers has been documented, and some researchers have raised theoretical concerns about whether the preserved "frozen" bone structure affects long-term bone quality. No clinical fracture excess attributable to over-suppression has been reported in pediatric cohorts, but treatment duration beyond 3 years is not supported by evidence and may carry risk without additional benefit.

Hypocalcemia

Bisphosphonates can transiently lower serum calcium, especially if vitamin D insufficiency is present at initiation. Serum calcium and phosphate should be measured within 2 to 4 weeks of starting therapy in adolescents, as growing teenagers have higher calcium demands than adults. Symptomatic hypocalcemia (muscle cramping, perioral tingling, Chvostek sign) requires immediate dose hold and repletion.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) is a bisphosphonate class effect documented primarily in adults receiving high-dose IV therapy for malignancy. The incidence with oral bisphosphonates at osteoporosis doses is estimated at less than 1 per 10,000 patient-years in adults [10]. No confirmed pediatric cases of alendronate-associated ONJ appear in the published literature as of early 2025, but the theoretical risk warrants a dental evaluation before treatment initiation and avoidance of invasive dental procedures during therapy when possible.

Atypical Femoral Fractures

Atypical subtrochanteric femoral fractures (AFF) are associated with prolonged bisphosphonate use in adults, typically after 5 or more years of continuous therapy [11]. No adolescent cases have been published. Nonetheless, limiting treatment to 2 to 3 years aligns with both the adult safety evidence and the pediatric expert opinion that most adolescents' underlying conditions (glucocorticoid exposure, for instance) may be time-limited.

Mental Health Monitoring

Adolescent clinical care always includes mental health screening. There is no established pharmacological link between alendronate and depression or anxiety, unlike some other agents used in bone disease. However, the chronic disease burden that drives bisphosphonate use (long-term steroid dependence, OI, neuromuscular disease) is itself associated with elevated depression rates in teenagers. Clinicians prescribing alendronate in this age group should ensure that mental health screening is part of routine follow-up, not as a drug side effect but as a standard of care for adolescents managing chronic illness.

Contraindications Specific to Adolescents

Several absolute contraindications apply with equal or greater force in this age group:

Hypocalcemia must be corrected before the first dose. Abnormalities of the esophagus that delay esophageal emptying (stricture, achalasia) are absolute contraindications. Inability to stand or sit upright for at least 30 minutes is a practical contraindication to oral alendronate; IV pamidronate or zoledronic acid are alternatives in non-ambulatory patients.

Creatinine clearance below 35 mL/min contraindicates alendronate per prescribing information [3]. Adolescents with chronic kidney disease stages 3b through 5 require nephrologist input before any bisphosphonate is considered.

Active pregnancy is a contraindication. As noted, Category D classification stems from animal reproductive toxicity data and the long skeletal half-life. Sexually active female adolescents must use reliable contraception throughout treatment.

Monitoring Schedule

Baseline labs before the first dose: serum calcium, phosphate, alkaline phosphatase, creatinine, and 25-OH vitamin D. DXA of the lumbar spine and total body less head (TBLH) with height and weight-specific Z-scores (not T-scores) should be the reference standard in this population per ISCD 2019 pediatric guidelines [12].

At 3 months: repeat serum calcium, phosphate. Bone turnover markers (serum CTX, P1NP) are optional but useful to confirm pharmacological response. At 12 months: repeat DXA, full metabolic panel, reassess fracture risk and indication for continued therapy. At 24 to 36 months: formal reassessment with specialist input on whether the treatment course should end. Most pediatric bone experts recommend a drug holiday after 2 to 3 years unless the underlying disease is persistent and fracture risk remains high.

Special Population: Osteogenesis Imperfecta

OI deserves a separate mention because it accounts for a large share of pediatric bisphosphonate use. OI types I, III, and IV all feature defective type I collagen synthesis and vary widely in severity. IV pamidronate is the most studied agent in OI. Oral alendronate is a reasonable alternative in OI type I (the mildest form) in ambulatory patients who can follow the oral protocol. Glorieux's 2001 cohort (N=30, ages 3 to 16) showed 3-year cyclic pamidronate reduced fracture rate by 40% compared to historical controls and improved lumbar BMD Z-score by 1.4 SD [8]. While that trial used IV pamidronate, it anchors the evidence that bisphosphonate-class intervention improves outcomes in OI, and the oral route has been validated as non-inferior in milder phenotypes.

Glucocorticoid-Induced Osteoporosis in Adolescents

Systemic glucocorticoids remain the most common drug-induced cause of secondary osteoporosis across all age groups. Prednisolone at 5 mg/day or more for 3 months or longer produces measurable BMD reduction even in teenagers. Inflammatory bowel disease, nephrotic syndrome, severe asthma, rheumatologic conditions, and solid organ transplantation are the main drivers of prolonged adolescent glucocorticoid exposure.

The ACR 2017 guidelines rate the quality of evidence for bisphosphonate use in pediatric glucocorticoid-induced osteoporosis as low-to-very-low but still recommend consideration in patients with significant BMD deficits or fractures [1]. "Clinicians should weigh the potential benefits of bisphosphonate therapy against the limited evidence for long-term outcomes in growing children," the guidelines state, a sentiment echoed by the British Society for Paediatric and Adolescent Rheumatology.

Early calcium and vitamin D optimization, steroid-dose minimization, and physical activity remain first-line interventions. Alendronate enters the picture when those measures are insufficient or fractures have already occurred.

Comparing Alendronate to Other Bisphosphonates in Adolescents

IV pamidronate (30 to 60 mg every 3 to 4 months) has the deepest published pediatric evidence base. Its disadvantages are IV access, hospital or infusion-center visits, acute-phase reactions (fever, myalgia, flu-like symptoms in 30 to 40% of first infusions), and cost.

IV zoledronic acid (0.05 mg/kg, max 4 mg, once yearly) has grown in use due to once-yearly dosing convenience. A head-to-head comparison with pamidronate in a 2011 trial by Otaify et al. found comparable BMD gains in OI patients over 12 months, with zoledronic acid showing fewer total infusion days [13].

Oral alendronate sits between these options: less invasive than IV agents, lower monitoring burden per visit, but dependent on adolescent adherence and GI tolerability. For an ambulatory 15-year-old with glucocorticoid-induced osteoporosis who can reliably follow dosing instructions, alendronate is a practical first choice. For a non-ambulatory 13-year-old with OI type III, IV pamidronate remains the standard.